Table 5.
Univariate analysis of survival
| HR | 95% CI | p Value | |
|---|---|---|---|
| Age (years) | 1.018 | 0.973 to 1.065 | 0.35 |
| Male sex | 1.083 | 0.50 to 2.345 | 0.84 |
| Duration of symptoms before admission (days) | 0.893 | 0.824 to 0.969 | 0.0066 |
| Smoking index (pack-years) | 0.9995 | 0.9989 to 1.0001 | 0.14 |
| IPF/non-IPF | 1.024 | 0.501 to 2.091 | 0.95 |
| Extent of ground-glass opacity (%) | 1.014 | 0.990 to 1.039 | 0.23 |
| Extent of honeycombing (%) | 1.031 | 1.004 to 1.06 | 0.023 |
| CLE (±) | 0.356 | 0.153 to 0.829 | 0.017 |
| PSE (±) | 0.785 | 0.392 to 1.574 | 0.50 |
| Lymphocyte (/μL) | 0.9996 | 0.9990 to 1.0002 | 0.22 |
| CRP (mg/dL) | 0.9929 | 0.947 to 1.041 | 0.77 |
| KL-6 (U/mL) | 1.000 | 0.9996 to 1.0004 | 0.88 |
| SP-D (ng/mL) | 1.0005 | 0.9992 to 1.0019 | 0.43 |
| BNP (pg/mL) | 1.001 | 0.9992 to 1.0028 | 0.27 |
| D-dimer (mg/mL) | 0.976 | 0.921 to 1.045 | 0.49 |
| PCT (ng/mL) | 1.889 | 1.063 to 3.545 | 0.030 |
| Pao2:Fio2 ratio on admission | 0.992 | 0.987 to 0.997 | 0.0038 |
| Pao2:Fio2 ratio on the day after glucocorticoid pulse therapy | 0.989 | 0.984 to 0.994 | 1.75×10−5 |
| SIRS (±) | 11.85 | 3.551 to 39.54 | 5.78×10−5 |
| Number of SIRS criteria | 1.98 | 1.448 to 2.707 | 1.87×10−5 |
Cox proportional hazards regression models were used for the statistical analysis.
BNP, brain natriuretic peptide; CLE, centrilobular emphysema; CRP, C reactive protein; IPF, idiopathic pulmonary fibrosis; KL-6, Krebs von den Lungen-6; PCT, procalcitonin; PSE, paraseptal emphysema; SIRS, systemic inflammatory response syndrome; SP-D, surfactant protein D.